Skip to content
Screener

Net Income at other companies

Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$89M+89.4%
Scilex Holding Company logo
Scilex Holding CompanySCLX
-$45.65M-75.0%
AVN
AVNSAVNS
$5.1M-22.7%
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$2.92M-39.4%
Bioventus logo
BioventusBVS
$33.44M+348%
Organon logo
OrganonOGN
$146M+67.8%

Segments

By segment

See full
Segment-$15.05M-226%

Other financials

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$944.15M-1.3%
Enterprise value$798.74M-3.1%
P/E19.7×-6.7×
P/S1.2×-0.2×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053851
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest income2,2892,3835,9954,608
(Loss) income before income taxes(13,532)17,0255,20820,147
Provision for income taxes1,5195,0425,7635,747
Net (loss) income$(15,051)$11,983$(555)$14,400
(Loss) earnings per share — basic$(0.46)$0.38$(0.02)$0.45
Weighted-average shares — basic32,460,78331,810,61232,275,15931,802,222
(Loss) earnings per share — diluted$(0.46)$0.34$(0.02)$0.44
Weighted-average shares — diluted32,460,78339,075,70332,275,15939,283,297

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s net income?
Collegium Pharmaceutical, Inc. (COLL) reported net income of -$15.05M in Q2 2026.
How has Collegium Pharmaceutical, Inc.'s net income changed year-over-year?
Collegium Pharmaceutical, Inc.'s net income decreased by 225.6% year-over-year, from $11.98M to -$15.05M.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s net income?
Over 4 years (2021 to 2025), Collegium Pharmaceutical, Inc.'s net income has grown at a -3.2% compound annual growth rate (CAGR), from $71.52M to $62.87M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Collegium Pharmaceutical, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude